Global Next Generation Sequencing (NGS) Market Analysis

The global Next-Generation Sequencing (NGS) market is expected to reach a value of approximately US$ 34.19 billion by 2030, according to Renub Research. This market is set to expand at a CAGR of 18.16% from 2024 to 2030. NGS technology has revolutionized genomics by enabling high-throughput DNA sequencing, dramatically reducing the time and cost involved in genetic research, diagnostics, and personalized medicine. With its ability to sequence multiple DNA fragments in parallel, NGS has transformed the fields of genomics, biology, medicine, and agriculture, unlocking new potential for precision medicine, disease diagnostics, and scientific research.

Request a free sample copy of the report: https://www.renub.com/next-generation-sequencing-market-p.php

Key Drivers of the NGS Market Growth

1. Rising Adoption of NGS in Diagnostics and Personalized Medicine

One of the primary factors driving the growth of the NGS market is its increasing adoption in clinical diagnostics. NGS allows for the comprehensive analysis of genetic data, enabling precise diagnostics and tailored treatment plans. The ability to analyze entire genomes or targeted genetic regions has made NGS indispensable in diagnosing a variety of diseases, including cancer, rare genetic disorders, and infectious diseases. As healthcare shifts toward precision medicine, the demand for NGS-based diagnostics continues to grow.

2. Technological Advancements and Cost Reductions

Advancements in sequencing technology and the reduction in sequencing costs have made NGS more accessible for a broader range of applications. The transition from older technologies, such as microarrays, to NGS is accelerating, as NGS offers higher accuracy, better throughput, and greater cost-effectiveness. In fact, NGS systems are now replacing older platforms for genomic evaluation in both clinical and research settings. This trend is expected to continue, driving further market growth.

3. NGS's Role in Oncology and Infectious Disease Research

NGS technologies are particularly valuable in oncology, where they are used for tumor mutation profiling, cancer genomics, and liquid biopsy applications. Similarly, NGS has become an essential tool in studying infectious diseases, allowing for the identification of pathogens, monitoring disease outbreaks, and developing vaccines. As these applications expand, the market for NGS in oncology and infectious disease research is projected to grow significantly.

Market Segmentation

1. By Products

The global NGS market is divided into three main product categories:

• Instruments
• Reagents and Consumables
• Services

Among these, the reagents and consumables segment holds the largest share, driven by the recurrent need for sample preparation kits, target enrichment kits, and other consumables that are integral to NGS workflows. Reagents and consumables are critical for both commercial and research applications of NGS, including clinical diagnostics and cancer research. As pharmaceutical companies and research institutes increasingly adopt NGS technologies, the demand for reagents and consumables continues to rise.

2. By Application

NGS has numerous applications across various sectors:

• Diagnostics (including oncology, rare diseases, and prenatal screening)
• Agriculture and Animal Research
• Drug Discovery
• Personalized Medicine and Genetic Screening
• Others

The diagnostic segment is one of the largest and most critical contributors to the NGS market. NGS’s ability to detect genetic variations makes it indispensable in the diagnosis and treatment of various diseases. In particular, oncology, genetic disorders, and infectious diseases are major areas benefiting from NGS, contributing significantly to market growth. As healthcare systems continue to prioritize genomic-driven treatments and precision medicine, NGS is becoming an essential tool in medical diagnostics.

3. By Technology

The NGS market can also be segmented by technology, with the most prominent being:

• Sequencing by Synthesis (SBS)
• Ion Semiconductor Sequencing
• Single-Molecule Real-Time (SMRT) Sequencing
• Nanopore Sequencing
• Others

Sequencing by Synthesis (SBS) is the most widely used NGS technology, known for its high accuracy, scalability, and cost-effectiveness. SBS enables large-scale genomic analyses and is favored in both research and clinical settings due to its efficiency and low error rate. As the demand for genomic analysis expands across various fields, SBS will continue to dominate the NGS technology landscape.

4. By End-User

NGS technologies are used across a variety of sectors, including:

• Academic and Clinical Research Centers
• Pharmaceutical and Biotechnology Companies
• Hospitals and Clinics
• Others

The academic and clinical research centers segment is anticipated to grow the fastest due to the increasing use of NGS in cancer research, genomics, and genetic variation studies. NGS enables the identification of new cancer-associated genes, the examination of tumor heterogeneity, and the analysis of genomic alterations that contribute to cancer development. As research and clinical applications expand, this segment will continue to see significant growth.

Regional Insights

1. North America

The United States is expected to dominate the global NGS market, thanks to its advanced healthcare infrastructure, strong research capabilities, and significant investments in genomics. The U.S. is home to some of the largest players in the NGS industry, including Illumina, Thermo Fisher Scientific, and Pacific Biosciences. The growing adoption of NGS in clinical diagnostics and precision medicine is particularly pronounced in North America, with oncology and infectious disease research driving the majority of growth. The U.S. has also created a favorable environment for NGS adoption with extensive funding, regulatory support, and a thriving biotechnology industry.

2. Europe

Europe is witnessing rapid advancements in NGS methodologies, particularly in oncology and infectious disease applications. The region has strong research and healthcare systems that are increasingly adopting NGS technology for disease diagnosis and treatment. Countries like the United Kingdom, Germany, and France are leading the way in integrating NGS into clinical workflows and research.

3. Asia-Pacific

The Asia-Pacific region is expected to experience significant growth in the NGS market, driven by increased investments in healthcare infrastructure, rising adoption of advanced technologies, and growing research activities. Countries like China, India, and Japan are emerging as key players in the NGS market. As healthcare systems in these countries evolve, the demand for NGS technologies is expected to rise, particularly in fields like personalized medicine, genetic research, and oncology.

Key Players

Prominent companies operating in the global NGS market include:

• Illumina
• Thermo Fisher Scientific
• Pacific Biosciences
• QIAGEN N.V.
• Roche
• Bio-Rad Laboratories
• Takara Bio Inc.
• Hamilton Company
• Geneious
• BioMérieux SA

Recent Developments

• December 2023: Illumina partnered with the African Society for Laboratory Medicine to improve access to genomics in Africa for combating infectious diseases.
• March 2023: SOPHiA GENETICS and QIAGEN teamed up to enhance tumor analysis with NGS-based assays on the DDM platform.
• September 2022: Predicine, Inc. received FDA breakthrough device designation for its cfDNA assay used in tumor mutation profiling via NGS in liquid biopsy samples.

Related Report :

Acute Respiratory Distress Syndrome Market

Global Clinical Chemistry Analyzer Market

Urinary Tract Infection Treatment Market

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)

Email: mailto:rajat@renub.com